Results 61 to 70 of about 82,231 (299)

Identification of New Drug Candidates Against \u3cem\u3eBorrelia burgdorferi\u3c/em\u3e Using High-Throughput Screening [PDF]

, 2016
Lyme disease is the most common zoonotic bacterial disease in North America. It is estimated that .300,000 cases per annum are reported in USA alone. A total of 10%–20% of patients who have been treated with antibiotic therapy report the recrudescence of
Babar, Mustafeez Mujtaba, Inayathullah, Mohammed, Kim, K. M., Parekh, Mansi B., Pothineni, Venkata Raveendra, Rajadas, Jayakumar, Samineni, A. V., Solow-Cordero, David, Tayebi, Lobat, Wagh, Dhananjay   +9 more
core   +3 more sources

IMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion

Molecular Oncology, EarlyView.
Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.
Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd   +9 more
wiley   +1 more source

Disruptive Strategies for Removing Drug Discovery Bottlenecks [PDF]

, 2012
Drug Discovery is shifting focus from the industry to outside partners and in the process creating new bottlenecks, suggesting the need for a more disruptive overhaul.
Antony Williams, Chris Waller, Mary Bradley, Sean Ekins, Sean Ekins   +4 more
core   +2 more sources

Drug repurposing in cancer

Pharmacological Research, 2017
Cancer is a major health issue worldwide, and the global burden of cancer is expected to increase in the coming years. Whereas the limited success with current therapies has driven huge investments into drug development, the average number of FDA approvals per year has declined since the 1990s.
Linda, Sleire, Hilde Elise, Førde, Inger Anne, Netland, Lina, Leiss, Bente Sandvei, Skeie, Per Øyvind, Enger   +5 more
openaire   +2 more sources

Metformin promotes mitochondrial integrity through AMPK‐signaling in Leber's hereditary optic neuropathy

FEBS Open Bio, EarlyView.
Metformin mediates mitochondrial quality control in Leber's hereditary optic neuropathy (LHON) fibroblasts carrying mtDNA mutations. At therapeutic levels, metformin activates AMPK signaling to restore mitochondrial dynamics by promoting fusion and restraining fission, while preserving mitochondrial mass, enhancing autophagy/mitophagy and biogenesis ...
Chatnapa Panusatid, Rapasviranda Soiyangsuk, Maneeluck Tanadjindarat, Chayanon Peerapittayamongkol   +3 more
wiley   +1 more source

A Unified Explanation for Drug Repurposing and Pharmacological Pleiotropy Based on Classical and Statistical Thermodynamics

Pharmacology Research & Perspectives
Drug repurposing is an authentic, emerging, and growing aspect of drug development when the demand for new therapeutic solutions is high. Many repurposed drugs have been discovered by serendipity or a non‐ordered process driven by chance and sharp ...
Richard Head, Saiful Islam, Jennifer H. Martin   +2 more
doaj   +1 more source

The benefits of in silico modeling to identify possible small-molecule drugs and their off-target interactions [PDF]

, 2018
Accepted for publication in a future issue of Future Medicinal Chemistry.The research into the use of small molecules as drugs continues to be a key driver in the development of molecular databases, computer-aided drug design software and collaborative ...
Blomberg N, Choi SH, Hastings J, Hirschey J, Mire Zloh, Stewart B Kirton, Wang X   +6 more
core   +2 more sources

Repurposing of approved cardiovascular drugs [PDF]

Journal of Translational Medicine, 2016
Research and development of new drugs requires both long time and high costs, whereas safety and tolerability profiles make the success rate of approval very low. Drug repurposing, applying known drugs and compounds to new indications, has been noted recently as a cost-effective and time-unconsuming way in developing new drugs, because they have ...
Junichi Ishida, Masaaki Konishi, Nicole Ebner, Jochen Springer   +3 more
openaire   +3 more sources

Digital twins to accelerate target identification and drug development for immune‐mediated disorders

FEBS Open Bio, EarlyView.
Digital twins integrate patient‐derived molecular and clinical data into personalised computational models that simulate disease mechanisms. They enable rapid identification and validation of therapeutic targets, prediction of drug responses, and prioritisation of candidate interventions.
Anna Niarakis, Philippe Moingeon
wiley   +1 more source

Protein sequence analysis in the context of drug repurposing

BMC Medical Informatics and Decision Making
Motivation Drug repurposing speeds up the development of new treatments, being less costly, risky, and time consuming than de novo drug discovery. There are numerous biological elements that contribute to the development of diseases and, as a result, to ...
Natalia García Sánchez, Esther Ugarte Carro, Lucía Prieto-Santamaría, Alejandro Rodríguez-González   +3 more
doaj   +1 more source